Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3 Trial of SRG-514 Administered Intraoperatively to the Site of Tumor Resection in Patients Undergoing Breast-Conserving Surgery for Triple Negative Breast Cancer

NCT07723469 is registered in ClinicalTrials.gov with SURGE Therapeutics as lead sponsor.

NCT NCT07723469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3 Trial of SRG-514 Administered Intraoperatively to the Site of Tumor Resection in Patients Undergoing Breast-Conserving Surgery for Triple Negative Breast Cancer
Lead sponsor
SURGE Therapeutics
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2034
Enrollment
400 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer